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Abstract
Background: Several lines of evidence have implicated the pro-inflammatory cytokine interleukin-1beta (IL-1b)i n
the etiology of schizophrenia. Although a number of genetic association studies have been reported, very few
have systematically examined gene-wide tagging polymorphisms.
Methods: A total of 533 patients with schizophrenia (302 males: mean age ± standard deviation 43.4 ± 13.0 years;
233 females; mean age 44.8 ± 15.3 years) and 1136 healthy controls (388 males: mean age 44.6 ± 17.3 years; 748
females; 46.3 ± 15.6 years) were recruited for this study. All subjects were biologically unrelated Japanese
individuals. Five tagging polymorphisms of IL-1b gene (rs2853550, rs1143634, rs1143633, rs1143630, rs16944) were
examined for association with schizophrenia.
Results: Significant difference in allele distribution was found between patients with schizophrenia and controls for
rs1143633 (P = 0.0089). When the analysis was performed separately in each gender, significant difference between
patients and controls in allele distribution of rs1143633 was observed in females (P = 0.0073). A trend towards
association was also found between rs16944 and female patients with schizophrenia (P = 0.032).
Conclusions: The present study shows the first evidence that the IL-1b gene polymorphism rs1143633 is
associated with schizophrenia susceptibility in a Japanese population. The results suggest the possibility that the
influence of IL-1b gene variations on susceptibility to schizophrenia may be greater in females than in males.
Findings of the present study provide further support for the role of IL-1b in the etiology of schizophrenia.
Background
Several lines of evidence suggest that pro-inflammatory
cytokine interleukin-1beta (IL-1b) is implicated in the
etiology and pathophysiology of schizophrenia. Although
studies investigating peripheral levels of IL-1b in schizo-
phrenic patients have reported inconsistent results [1-6], a
study examining the cerebrospinal fluid has shown a
marked elevation of IL-1b in patients with first-episode
schizophrenia compared to healthy controls [7]. Kowalski
et al [8] reported that the release of IL-1b by peripheral
monocytes was increased before treatment and then nor-
malized by antipsychotic medication in patients with schi-
zophrenia. Recently, Liu et al. [9] showed that IL-1b in the
peripheral blood mononuclear cells was overexpressed not
only in schizophrenia patients but also in their siblings,
suggesting the involvement of the hereditary factors.
Furthermore, previous findings suggested that IL-1b may
be involved in the possible link between prenatal exposure
to infection and schizophrenia [10,11].
The IL-1b gene is located in a region on 2q14. This
region has consistently shown positive linkage findings in
schizophrenia. Many studiesh a v er e p o r t e dt h i sr e g i o n
among their largest results [12,13]. Furthermore, Lewis et
al [14] have shown in their meta-analysis of 20 genome
scans that 2p12-q22.1 was associated with a genomewide
significant P value. Linkage of this region with schizo-
phrenia in an Asian population has also been reported
[15].
A number of genetic association studies have sug-
gested that genetic variation of the IL-1b gene might
confer susceptibility to schizophrenia. Three studies in
Caucasian populations reported a significant association
of schizophrenia with an IL-1b gene polymorphism
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firmed in other studies [19,20]. Furthermore, none of
the previous studies in Asian populations have obtained
evidence for an association between IL-1b gene and
schizophrenia [21-23]. All of the aforementioned asso-
ciation studies, except for that of Shirts, et al. [19],
examined only rs16944 and/or rs1143634. Therefore,
t h er o l eo fo t h e rIL-1b gene polymorphisms remains to
be determined. We here examined 5 tagging polymorph-
isms of the IL-1b gene for an association with schizo-
phrenia in a Japanese sample.
Methods
Subjects
Subjects were 533 patients with schizophrenia (302
males: mean age ± standard deviation 43.4 ± 13.0 years;
233 females; mean age 44.8 ± 15.3 years) and 1136
healthy controls (388 males: mean age 44.6 ± 17.3 years;
748 females; 46.3 ± 15.6 years). The mean age at onset
was 23.9 ± 8.0 and 25.8 ± 9.8 years for male and female
patients, respectively. All subjects were biologically unre-
lated Japanese individuals, based on their self-reports,
and were recruited from the outpatient clinic of the
National Center of Neurology and Psychiatry Hospital,
Tokyo, Japan or through advertisements in free local
information magazines and by our website announce-
ment. Consensus diagnosis by at least two psychiatrists
was made for each patient according to the Diagnostic
and Statistical Manual of Mental Disorders, 4
th edition
criteria [24], on the basis of unstructured interviews and
information from medical records. The controls were
healthy volunteers with no current or past history of psy-
chiatric treatment, and were screened using the Japanese
version of the Mini International Neuropsychiatric Inter-
view (M.I.N.I.) [25,26] by a research psychiatrist to rule
out any axis I psychiatric disorders. Participants were
excluded if they had prior medical histories of central
nervous system disease or severe head injury, or if they
met the criteria for substance abuse or dependence, or
mental retardation. The study protocol was approved by
the ethics committee at the National Center of Neurol-
ogy and Psychiatry, Japan. After description of the study,
written informed consent was obtained from every sub-
ject. Most of the subjects had participated in our previous
genetic association studies [27,28]. Some of the control
subjects had also participated in our previous studies
which examined IL-1b gene polymorphisms [29,30].
Genotyping
Five tagging single nucleotide polymorphisms (SNPs)
(rs2853550, rs1143634, rs1143633, rs1143630, rs16944)
in a region 1 kilobase (kb) upstream to 1 kb down-
stream of the IL-1b gene (chromosome 2: 113,302,808 -
113,311,827 bp) were selected by Haploview 4.2 [31]
using Japanese and Chinese population in the HapMap
SNP set (version 22), at an r
2 threshold of 0.80 with a
minor allele frequency greater than 0.1. Genomic DNA
was prepared from the venous blood according to stan-
dard procedures. The SNPs were genotyped using the
TaqMan 5’-exonuclease allelic discrimination assay.
Thermal cycling conditions for polymerase chain reac-
tion were 1 cycle at 95°C for 10 minutes followed by 50
cycles of 92°C for 15 seconds and 60°C for 1 minute.
The allele-specific fluorescence was measured with ABI
PRISM 7900 Sequence Detection Systems (Applied Bio-
systems, Foster city, CA, USA). Genotype data were
read blind to the case-control status. Ambiguous geno-
type data were not included in the analysis. The call
rates for each SNP ranged from 97.7% to 98.6%. The
genotyping failure rate for all SNPs combined was < 2%.
In 92 subjects, all 5 SNPs were genotyped in duplicate
to ensure genotyping accuracy, and the concordance
rate of called genotypes was over 99%.
Statistical analysis
Deviations of genotype distributions from the Hardy-
Weinberg equilibrium (HWE) were assessed with the
exact test described by Wigginton et al [32]. Genotype
and allele distributions were compared between patients
and controls by using the c
2 test for independence or
with Fisher’s exact test. The above statistical analyses
were performed using PLINK version 1.07 [33].
Haploview 4.2 [31] was used to estimate haplotype fre-
quencies and linkage disequilibrium (LD) coefficients.
Haplotypes with frequencies > 1% were included in the
association analysis. Permutation procedure (10,000 repli-
cations) was used to determine the empirical significance.
Statistical tests were two tailed and statistical signifi-
cance was considered when P < 0.05. Significance level
corrected for multiple comparisons of 5 SNPs was set at
P <0 . 0 1 3b yam e t h o dp r o p o s e db yL ie ta l[ 3 4 ] ,w h i c h
was calculated using SNPSpD (SNP Spectral Decompo-
sition) software [35].
Power calculations were performed using the Power
Calculator for Two Stage Association Studies (http://
www.sph.umich.edu/csg/abecasis/CaTS/). Power was cal-
culated under prevalence of 0.01 using an allelic model
with an alpha level of 0.05. Assuming disease allele fre-
quencies of 0.20 and 0.40, our sample had 80% statistical
power to detect relative risks of 1.28 and 1.23, respec-
tively. Similarly, we had 90% power to detect relative
risks of 1.33 and 1.27.
Since several aspects of immunity have marked sex
differences [36], analyses were performed not only for
the entire sample but also for each gender separately.
Assuming allele frequency of 0.40, male and female
samples each had 80% statistical power to detect relative
risks of 1.35 and 1.34, respectively.
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Genotype and allele distributions of the examined SNPs
for the entire sample, males, and females are shown in
Table 1, 2, and 3, respectively. The genotype distributions
did not significantly deviate from the HWE in any of the
SNPs examined. Significant differences in genotype and
allele distributions were found between the patients with
schizophrenia and controls for rs1143633. The C allele
w a ss i g n i f i c a n t l ym o r ec o m m o ni np a t i e n t st h a ni nc o n -
trols (odds ratio 1.22, 95% confidence interval (CI) 1.05
to 1.41, P = 0.0089). This association remained significant
after correcting for multiple testing of 5 SNPs (corrected
P = 0.013). When the analysis was performed separately
in each gender, significant difference between patients
and controls in allele distribution of rs1143633 was
observed only in females (odds ratio 1.34, 95% CI 1.08 to
1.66, P = 0.0073). The A allele of rs16944 also showed a
trend towards association with schizophrenia in female
subjects (odds ratio 1.26, 95% CI 1.02 to 1.56, P = 0.032).
Linkage disequilibrium (LD) coefficients (D’ and r
2)
and haplotype blocks are shown in Figure 1. Results of
the haplotype association analyses are shown in Table 4.
No significant difference in haplotype distribution was
found between patients with schizophrenia and controls
(all P > 0.05 by permutation test).
Discussion
To our knowledge, the present study is the largest study
to date that examined the IL-1b gene polymorphisms for
association with schizophrenia. The results provide the
first evidence suggesting that the C allele of rs1143633 is
associated with schizophrenia.
The study in a United States population by Shirts et al
[19] was the only one that previously examined the asso-
ciation of schizophrenia with rs1143633, in which no sig-
nificant difference was found in allele frequencies
between patients and controls. Although Watanabe et al
[23] have also examined 9 SNPs of the IL-1 gene complex
in Japanese subjects, none of the SNPs examined in their
study was in remarkable linkage disequilibrium with
rs1143633 or rs16944 (all r
2 <0 . 1b a s e do nH a p M a p
Japanese and Han Chinese population data, release 22).
The inconsistent results regarding the effect of rs1143633
between Shirts, et al [19] and our study may be attributa-
ble to ethnic difference. Indeed, a recent meta-analysis
has shown a significant association of the G allele of
rs16944 and the G allele carrier status of rs1143634 with
a risk of schizophrenia in Caucasian, but not in Asian,
populations [37]. Our samples provided sufficient power
to detect relatively small relative risks, and therefore sug-
gest that rs16944 and rs1143634 have no major effect on
Table 1 Association analysis of the 5 SNPs in both genders combined
Males
SNP name Allele 1/2 N Genotype Allele P-value HWE P-value
1/1 1/2 2/2 1 2 Genotype Allele
rs2853550 A/G Schizophrenia 531 9 128 394 146 916 0.23 0.088 0.86
(0.02) (0.24) (0.74) (0.14) (0.86)
Controls 1115 14 232 869 260 1970 0.88
(0.01) (0.21) (0.78) (0.12) (0.88)
rs1143634 A/G Schizophrenia 525 1 41 483 43 1007 0.97
(a) 0.90 0.59
(0.00) (0.08) (0.92) (0.04) (0.96)
Controls 1121 2 90 1029 94 2148 1.00
(0.00) (0.08) (0.92) (0.04) (0.96)
rs1143633 C/T Schizophrenia 524 111 249 164 471 577 0.035 0.0089 0.38
(0.21) (0.48) (0.31) (0.45) (0.55)
Controls 1123 188 525 410 901 1345 0.38
(0.17) (0.47) (0.37) (0.40) (0.60)
rs1143630 T/G Schizophrenia 520 13 140 367 166 874 0.88 0.66 1.00
(0.03) (0.27) (0.71) (0.16) (0.84)
Controls 1119 24 296 799 344 1894 0.65
(0.02) (0.26) (0.71) (0.15) (0.85)
rs16944 A/G Schizophrenia 521 123 253 145 499 543 0.18 0.060 0.54
(0.24) (0.49) (0.28) (0.48) (0.52)
Controls 1111 226 534 351 986 1236 0.39
(0.20) (0.48) (0.32) (0.44) (0.56)
(a) Calculated using Fisher’s exact test.
SNP: single nucleotide polymorphism; HWE: Hardy-Weinberg Disequilibrium
Numbers in parentheses represent the frequencies of genotypes and alleles.
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Males
SNP name Allele 1/2 N Genotype Allele P-value HWE P-value
1/1 1/2 2/2 1 2 Genotype Allele
rs2853550 A/G Schizophrenia 300 4 74 222 82 518 0.68
(a) 0.69 0.62
(0.01) (0.25) (0.74) (0.14) (0.86)
Controls 383 7 85 291 99 667 0.82
(0.02) (0.22) (0.76) (0.13) (0.87)
rs1143634 A/G Schizophrenia 298 0 24 274 24 572 0.81
(a) 0.82 1.00
(0.00) (0.08) (0.92) (0.04) (0.96)
Controls 383 1 27 355 29 737 0.42
(0.00) (0.07) (0.93) (0.04) (0.96)
rs1143633 C/T Schizophrenia 299 59 145 95 263 335 0.43 0.47 0.81
(0.20) (0.48) (0.32) (0.44) (0.56)
Controls 383 77 168 138 322 444 0.059
(0.20) (0.44) (0.36) (0.42) (0.58)
rs1143630 T/G Schizophrenia 295 7 81 207 95 495 0.75 0.73 1.00
(0.02) (0.27) (0.70) (0.16) (0.84)
Controls 383 6 106 271 118 648 0.32
(0.02) (0.28) (0.71) (0.15) (0.85)
rs16944 A/G Schizophrenia 295 66 143 86 275 315 0.92 0.67 0.64
(0.22) (0.48) (0.29) (0.47) (0.53)
Controls 385 82 186 117 350 420 0.61
(0.21) (0.48) (0.30) (0.45) (0.55)
(a) Calculated using Fisher’s exact test.
SNP: single nucleotide polymorphism; HWE: Hardy-Weinberg Disequilibrium
Numbers in parentheses represent the frequencies of genotypes and alleles.
Table 3 Association analysis of the 5 SNPs in females
Males
SNP name Allele 1/2 N Genotype Allele P-value HWE P-value
1/1 1/2 2/2 1 2 Genotype Allele
rs2853550 A/G Schizophrenia 231 5 54 172 64 398 0.18 0.096 0.78
(0.02) (0.23) (0.74) (0.14) (0.86)
Controls 732 7 147 578 161 1303 0.57
(0.01) (0.20) (0.79) (0.11) (0.89)
rs1143634 A/G Schizophrenia 227 1 17 209 19 435 0.46
(a) 0.84 0.32
(0.00) (0.07) (0.92) (0.04) (0.96)
Controls 738 1 63 674 65 1411 1.00
(0.00) (0.09) (0.91) (0.04) (0.96)
rs1143633 C/T Schizophrenia 225 52 104 69 208 242 0.013 0.0073 0.29
(0.23) (0.46) (0.31) (0.46) (0.54)
Controls 740 111 357 272 579 901 0.76
(0.15) (0.48) (0.37) (0.39) (0.61)
rs1143630 T/G Schizophrenia 225 6 59 160 71 379 0.97 0.83 0.80
(0.03) (0.26) (0.71) (0.16) (0.84)
Controls 736 18 190 528 226 1246 0.89
(0.02) (0.26) (0.72) (0.15) (0.85)
rs16944 A/G Schizophrenia 226 57 110 59 224 228 0.11 0.032 0.69
(0.25) (0.49) (0.26) (0.50) (0.50)
Controls 726 144 348 234 636 816 0.50
(0.20) (0.48) (0.32) (0.44) (0.56)
(a) Calculated using Fisher’s exact test.
SNP: single nucleotide polymorphism; HWE: Hardy-Weinberg Disequilibrium
Numbers in parentheses represent the frequencies of genotypes and alleles. Significant P-values (< 0.013) are shown in boldface.
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is consistent with the previous Asian findings [21-23].
However, there was a trend of association of rs16944, in
the opposite direction to that of the Caucasians, with
schizophrenia susceptibility in female subjects. Therefore,
there remains a possibility that a larger study would yield
a significant difference between Japanese female schizo-
phrenic patients and controls in the allele frequency of
rs16944.
A number of genome-wide association studies (GWAS)
have searched for polymorphisms associated with schizo-
phrenia [38-43]. Although no evidence of association
with IL-1b gene has been reported, common risk alleles
in the major histocompatibility region on chromosome 6,
which is involved in the immune response, have shown
statistically significant evidence of association [38-40].
Furthermore, a genome-wide pharmacogenomic study
has shown that IL-1a rs11677416, which is in weak LD
with rs1143633 (r
2 = 0.094, D’ = 0.809 based on HapMap
Japanese and Han Chinese population data, release 22),
was associated with response of neurocognitive symp-
toms to antipsychotic treatment [44]. These findings,
together with ours, suggest genetic influence on immune
alterations in schizophrenia.
A shift towards the T helper type 2 (Th2) system has
been indicated in schizophrenia [45-47]. IL-1b stimulates
a. SNPs in the promoter region
b. Intronic SNPs
c. Synonymous SNPs
Figure 1 Haplotype block structure of the IL-1b gene.G e n o m i c
organization and linkage disequilibrium (LD) structure of the IL-1b
gene are shown. Exons are shown as boxes. Shades of red
represent extent of LD (darker red denotes D’ = 1). Numbers in
squares give r
2 values multiplied by 100.
Table 4 Haplotype analysis of IL-1b gene polymorphisms
Males Females
Block Haplotype Diagnosis Carrier Non-
carrier
c2 Nominal P
value
Permutation
P value
Carrier Non-
carrier
c2 Nominal P
value
Permutation
P value
GT Schizophrenia 336.3 265.7 0.557 0.456 0.957 251.0 213.0 6.240 0.0125 0.118
(0.559) (0.441) (0.541) (0.459)
Controls 447.9 326.1 901.0 585.0
(0.579) (0.421) (0.606) (0.394)
1 GC Schizophrenia 183.1 418.9 0.216 0.642 0.995 149.0 315.0 2.298 0.130 0.691
(0.304) (0.696) (0.321) (0.679)
Controls 226.4 547.6 422.5 1063.5
(0.293) (0.707) (0.284) (0.716)
AC Schizophrenia 82.6 519.4 0.215 0.643 0.995 63.7 400.3 3.281 0.0701 0.461
(0.137) (0.863) (0.137) (0.863)
Controls 99.6 674.4 158.5 1327.5
(0.129) (0.871) (0.107) (0.893)
GG Schizophrenia 321.4 280.6 0.154 0.694 0.996 231.2 228.8 5.012 0.0252 0.207
(0.534) (0.466) (0.503) (0.497)
Controls 422.6 353.4 837.4 652.6
(0.545) (0.455) (0.562) (0.438)
2 GA Schizophrenia 183.5 418.5 0.040 0.841 1.00 156.4 303.6 5.326 0.0210 0.178
(0.305) (0.695) (0.340) (0.660)
Controls 232.7 543.3 422.8 1067.2
(0.300) (0.700) (0.284) (0.716)
TA Schizophrenia 97.1 504.9 0.081 0.776 0.999 72.4 387.6 0.027 0.869 1.00
(0.161) (0.839) (0.157) (0.843)
Controls 120.7 655.3 229.8 1260.2
(0.156) (0.844) (0.154) (0.846)
Numbers in parentheses represent the frequencies of haplotypes. Permutation P values were based on 10,000 permutations.
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tant cofactor for the induction of T-helper lymphocyte
activity towards Th2 direction. Significant increase in cir-
culating mRNA expression levels of IL-1b has been
observed in schizophrenic patients [9]. The changes in
mRNA levels may reflect the genetic variation in IL-1b
gene. The findings on biological roles of IL-1b poly-
morphisms, however, have not been consistent across
studies. A/A genotype of rs16944 has been associated
with higher gastric mucosa IL-1b levels in H. pylori posi-
tive population [48]. On the other hand, subjects with
G/G genotype showed an increased release of IL-1b from
mononuclear cells after stimulation with lipopolysacchar-
ide [49]. Recent studies suggest that the functional role of
rs16944 may depend on the IL-1b promoter region hap-
lotypes including rs16944 and rs1143627 [50-53].
Although the findings are inconsistent, these previous
studies suggest that rs16944 could affect the expression
levels of IL-1b. On the other hand, the influence of
rs1143633 on IL-1b expression levels has not been pre-
viously reported.
Intriguingly, rs1143633 and rs16944 have also been
associated with cortisol response to dexamethasone in
healthy subjects [30]. Alleles associated with increased
cortisol response to dexamethasone were shown to be
associated with schizophrenia in the present study.
Higher rates of non-suppression to dexamethasone com-
pared to healthy subjects have been reported in schizo-
phrenia [54] and schizotypy [55]. On the other hand,
Ismail et al [56] reported that less than 2% of their schi-
zophrenic patients were non-suppressors. Although the
findings are inconsistent, these studies indicate that
schizophrenia may be associated with alteration in
hypothalamic- pituitary- adrenal (HPA) axis. Taken
together, our findings suggest that IL-1b gene poly-
morphisms may play a role in the HPA axis alteration
in schizophrenic patients.
Our results showed significant association of rs1143633
with schizophrenia in only females. Although our male
sample was not large enough to detect a small relative
risk, our data suggest that susceptibility to schizophrenia
is more influenced by the IL-1b gene variation in females.
To our knowledge, no previous studies have examined
the gender differences in the association between IL-1b
gene polymorphisms and schizophrenia. However, gen-
der differences have been reported in the association
between schizophrenia and RELA gene [27] encoding the
major component of NF-B, which is activated by IL-1b.
Taken together with our results, the influence of IL-1b
on susceptibility to schizophrenia may differ between
genders. Indeed, gender differences in immunity have
been reported in previous studies [36]. IL-1 release from
mononucleated cells has been shown to be menstrual
phase dependent in females and lower in males [57].
Furthermore, in vitro stimulation of lymphocytes with
phytohemagglutinin has shown that females produce
more Th2 cytokines than males [58]. Thus, future studies
investigating associations of immune-related genes with
schizophrenia should take into consideration the possible
gender differences.
There are some limitations to this study. The ethnicity
of the participants was based on self-reports and was
not confirmed by genetic analyses. Our positive results
might be derived from sample bias due to population
stratification, although the Japanese are a relatively
homogeneous population. Furthermore, structured inter-
view such as SCID (Structured Clinical Interview for
DSM) was not used for diagnosis in this study. Finally,
the function of the IL-1b gene SNPs are unclear. Future
studies are necessary to elucidate the function and its
relationship with the pathogenesis of schizophrenia.
Conclusions
Our results suggest that rs1143633 of IL-1b gene is
associated with schizophrenia susceptibility in a Japanese
population and that the influence of IL-1b gene varia-
tions on susceptibility to schizophrenia may be greater
in females than in males. We obtained no significant
evidence for a well-studied polymorphism rs16944 being
associated with schizophrenia, which is consistent with
previous studies in Asian populations. However, a trend
of higher A allele frequency of rs16944 in female
patients with schizophrenia leaves open a possibility that
a larger study may yield a significant difference. The
results of the present study provide further support for
the role of IL-1b in the etiology of schizophrenia. Future
studies are warranted to replicate the present findings
and to reveal the functional role of IL-1b gene in patho-
physiology of schizophrenia.
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